ElevateBio

ElevateBio, established in 2019, is a biotechnology company focused on creating and operating a portfolio of cell and gene therapy companies. Headquartered in Cambridge, Massachusetts, the company collaborates with innovative scientists and inventors to advance novel therapeutic approaches. Its core mission involves developing cutting-edge cell and gene therapies, leveraging technology-driven platforms to address unmet patient needs. The company's product focus spans various therapeutic modalities, including cell therapy and gene therapy, aiming to bring transformative medicines to market.

Operating with a workforce of 500-1,000 employees across 2 locations, ElevateBio fosters an environment for research and development. The company's strategic approach involves building and scaling companies that can deliver on the promise of advanced therapies. Its commitment to scientific innovation is supported by a dedicated team, and interested parties can learn more by accessing Meet ElevateBio's team. This focus on operational excellence and team development is crucial for navigating the complex landscape of biotechnology.

With a reported revenue of $105.7M, ElevateBio demonstrates significant financial activity, underscored by substantial funding rounds totaling over $1.2 billion across Series A, B, C, and D. This financial backing supports its ambitious growth and development pipeline. The company operates within a competitive biotechnology sector, facing rivals such as Lyell Immunopharma, Humacyte, and Voyager Therapeutics. For a detailed overview of its financial performance and metrics, users can Explore financial highlights. ElevateBio's strategic investments and partnerships position it as a key player in the cell and gene therapy space.